Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javier Pagonabarraga has a total of 497 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sleep-like slow waves during wakefulness are associated with hallucinations and poorer cognition in Parkinson’s disease

    by Fosco Bernasconi, Thomas Andrillon, Juan Carlos Farah, Isabelle Arnulf, Sophie Schwartz, Jevita Potheegadoo, Saul Martínez-Horta, Javier Pagonabarraga, Jaime Kulisevsky, Olaf Blanke

    Slow waves during sleep are fundamental for neural homeostasis, metabolic regulation, and waste clearance and are known to be altered in neurodegenerative diseases. Sleep-like slow waves (SLSWs) have been observed in awake, healthy individuals, where they are linked to fluctuations in vigilance and mind-wandering. Whether SLSWs are altered in Parkinson’s disease (PD), and whether such alterations contribute to psychiatric or cognitive complications, remains unknown. In a cohort of 84 nondemented patients with PD and 30 healthy older adults, we found that SLSWs occurred more frequently in patients with PD. Hallucinatory traits in patients with PD were associated with higher SLSW amplitude, especially over frontocentral regions. Moreover, more prominent SLSWs were associated with poorer cognitive functions. We conclude that, whereas slow waves during sleep have positive physiological functions, exacerbated diurnal SLSWs may reflect responses related to PD neuropathology, at the cost of hallucinations and reduced cognitive function.

  • Open Access

    Neurofilament Light Chain and Mutant Huntingtin Across Huntington's Disease Integrated Staging System Stages in Huntington Disease: A Cross‐Sectional Multimodal Analysis

    by Jesús Pérez-Pérez, Gonzalo Olmedo-Saura, Arnau Puig Davi, Rocío Pérez González, Jordi Pegueroles, Andrea Horta-Barba, Anna Vázquez Oliver, Elisa Rivas Asensio, Daniel Alcolea, Juan Fortea, et al.

    Background: The Huntington's Disease Integrated Staging System (HD‐ISS) provides a framework for staging HD but does not incorporate fluid biomarkers. Objective: The aim of this study was to examine neurofilament light chain (NfL) and mutant huntingtin (mHTT) and total tau across HD‐ISS stages and their associations with genetic burden, neuroimaging, and clinical measures. Methods: We performed cross‐sectional analysis of the Barcelona‐Huntington's Disease (BCN‐HD) cohort with external replication in the multicenter HDClarity study. HD gene expansion carriers were classified as HD‐ISS stages 0 to 3. NfL (cerebrospinal fluid [CSF] and plasma), CSF mHTT, total tau, striatal volumes, and Unified Huntington's Disease Rating Scale measures were quantified. Group differences and associations were analyzed using adjusted models. Results: The BCN‐HD cohort included 78 participants (50 HD gene expansion carriers [HDGECs], 28 controls) and HDClarity included 218 participants (166 HDGECs, 52 controls). CSF NfL increased across HD‐ISS stages and discriminated premanifest from manifest individuals, as well as HD‐ISS stage 0 from stage 1. Plasma NfL showed parallel increases and strongly correlated with CSF NfL ( ρ = 0.88, P < 0.001). More than half of HD‐ISS 0 individuals had NfL levels above the age‐adjusted 95th percentile (P95) and shorter predicted time to onset (13 years for CSF and 10 years for plasma). From HD‐ISS 1 onward, NfL levels exceeded P95 in most individuals. Higher NfL concentrations were associated with genetic burden, striatal atrophy, and clinical measures (all P < 0.001). CSF mHTT was detectable from HD‐ISS 0 but showed weaker associations, whereas CSF total tau increased only from HD‐ISS 3. Conclusions: NfL identifies biological activity across the HD‐ISS continuum and shows neuroaxonal injury in a subset of individuals classified as stage 0. These findings suggest that fluid biomarkers may complement current HD‐ISS criteria and support biological stratification in observational studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    Association of α-synuclein seed-amplification kinetics with cognitive decline in idiopathic Parkinson's disease

    by Jon Rodriguez-Antiguedad, Arnau Puig-Davi, Iñigo Ruiz-Barrio, David Campo-Caballero, Elena Vacchi, Giorgia Melli, Lidia Bojtos, Carla Franch-Marti, Gonzalo Olmedo-Saura, Anna Vazquez-Oliver, et al.

  • Open Access

    Spanish expert consensus statement on the use of inhaled levodopa for the treatment of fluctuations in Parkinson’s disease

    by J. Pagonabarraga, M. Blázquez-Estrada, E. Freire-Álvarez, L. López-Manzanares, N. López-Ariztegui, Á. Sánchez-Ferro, D. Santos-García


  • Open Access

    Patient-specific functional networks track early cognitive alterations and minor hallucinations in Parkinson’s disease

    by Sara Stampacchia, Fosco Bernasconi, Dimitri Van De Ville, Enrico Amico, Lada Kohoutová, John-Paul Taylor, Alan Thomas, Javier Pagonabarraga, Jaime Kulisevsky, Olaf Blanke

    Minor hallucinations (MHs) affect up to 40% of patients with Parkinson’s disease (PD) and are early indicators of cognitive decline. Unlike previous group-level studies, connectome-based brain fingerprinting enables the capture of individualized neural features. Leveraging this framework in a cross-sectional cohort of patients with Parkinson’s disease with and without MHs using resting-state functional magnetic resonance imaging, here we show that each patient exhibits a unique brain fingerprint, irrespective of MH status. The most individualized features were associated with clinically relevant measures such as motor-symptom severity and cognitive performance. Patients with MHs showed a loss of individual-specific features in brain networks linked to cognitive health, whereas the cerebellar-to-cortex connectivity—typically less distinctive—became more prominent, emphasizing the role of somatosensory and motor integration in MH pathogenesis. Moreover, MH-related fingerprint regions mapped onto cortical territories with lower densities of neurotransmitter systems implicated in hallucinations. Overall, our fully data-driven findings reveal a distinct, patient-specific signature that differentiates patients with Parkinson’s disease and MHs.


  • Open Access

    Plasmatic immune extracellular vesicle profiles identify prodromal and early stages of Parkinson's disease

    by Elena Vacchi, Jacopo Burrello, Alessio Burrello, Sara Bolis, Inigo Ruiz-Barrio, Ilaria Bertaina, Luca Baldelli, Maria Giulia Bacalini, Giacomo Chiaro, Rudolf Kaelin, et al.

    Extracellular vesicles (EVs) hold promise as minimally invasive biomarkers for neurodegenerative proteinopathies, but disease- and stage-specific profiles remain unclear. For this study, we enrolled 378 participants across five centers and the MJFF-BioFIND cohort: 100 healthy controls [HC], 64 isolated REM sleep behavior disorder [iRBD], 41 DeNovo Parkinson's Disease [PD], 89 Late PD, 32 other Synucleinopathies, and 52 Tauopathies. All participants underwent clinical evaluation and blood collection. The 77 subjects from the BioFIND cohort also provided CSF samples. EV concentration and size were assessed by nanoparticle tracking analysis; flow cytometry quantified tetraspanins (CD9/CD63/CD81) and 37 surface markers. Multivariable logistic regression, receiver operating characteristic analyses (ROC), and repeated random forest (rRF) classifiers evaluated diagnostic utility. Late PD showed the highest EV concentrations compared to HC and other disease groups. Participants exhibited distinct EV surface immunophenotypes, with the iRBD group displaying the most extensive immune activation signature vs HC, followed by PD patients. Multivariate logistic regression analysis identified diagnostic marker panels: CD3/CD9/CD25/CD56 for iRBD, SSEA4 for Late PD, CD146/CD209 for Synucleinopathies, and CD8/CD45/CD62P for Tauopathies. ROC confirmed good discriminatory performance, with CD56 emerging as the strongest single predictor for iRBD vs HC, SSEA4 showing high sensitivity for Late PD, and marker combinations providing optimal balance for Synucleinopathy/Tauopathy classification vs HC. In the CSF BioFIND subset, Late PD EVs exhibited increased myeloid (CD1c), adhesion (CD29), activation (CD69), and epithelial (CD326) markers compared to HC. Among these, CD326 was independently associated with Late PD diagnosis. Machine learning classifiers using all 37 surface antigens achieved excellent training performance (91.7-94.3% accuracy for iRBD/Synucleinopathies vs HC) and maintained robust validation accuracy, particularly for iRBD (77.8%) and DeNovo PD (76.6%) vs HC. EV immuno-phenotyping reveals distinct signatures across the neurodegenerative proteinopathies spectrum, with the highest diagnostic utility for prodromal iRBD detection. Longitudinal validation and cell-of-origin refinement represent key next steps toward clinical translation.

  • Open Access

    Cognitive and behavioral disturbances in PSP and MSA: clinical features and imaging correlates

    by I. Ruiz-Barrio, A. Horta-Barba, S. Martinez-Horta, J. Kulisevsky, J. Pagonabarraga

    Cognitive and behavioral disturbances are increasingly recognized as core features of Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA), with important clinical and prognostic implications. In PSP, cognitive impairment—often an early sign—is dominated by a dysexecutive syndrome linked to dorsolateral prefrontal atrophy and fronto-subcortical circuit disruption. Deficits also extend to attention, memory, language, visuospatial abilities, and social cognition. Apathy is the most common behavioral symptom, associated with medial prefrontal and subcortical atrophy, while impulsivity, disinhibition, and mood symptoms reflect broader orbitofrontal and posterior cortical involvement. Imaging studies highlight frontooccipital white matter disruption and subcortical tau deposition as key contributors to these features. In MSA, cognitive impairment is typically milder and more variable, most commonly involving executive dysfunction related to fronto-subcortical and cerebellar degeneration. Memory and visuospatial issues usually stem from impaired executive control. Behavioral symptoms—especially apathy and depression—are frequent but underrecognized. Frontal and cerebellar atrophy, along with disrupted striato-frontal connectivity and reduced metabolism, correlate with these changes. Autonomic dysfunction, particularly orthostatic hypotension, may further exacerbate cognitive decline through cerebral hypoperfusion. These findings underscore the importance of early detection of cognitive and behavioral symptoms in PSP and MSA. Given their significant impact on quality of life and functional decline, comprehensive assessment tools and multidisciplinary care approaches are essential to improve outcomes.


  • Open Access

    Frontal subcortical executive dysfunction and minor hallucinations in Parkinson's disease are linked to sensitivity to somatomotor conflicts

    by Jevita Potheegadoo, Léa F Duong Phan Thanh, Fosco Bernasconi, Nathalie H Meyer, Laurent Jenni, Marie E Maradan-Gachet, Cyrille Stucker, Herberto Dhanis, Sabina Catalano Chiuvé, Julien F Bally, et al.

    Background: Minor hallucinations (MH) affect 30–60% of patients with Parkinson's disease (PD), and are considered precursors to structured visual hallucinations and cognitive decline. While the link between structured visual hallucinations and dementia is well established, the neuropsychological correlates of MH in PD remain unclear; most studies finding no significant cognitive differences between patients with MH and those without any hallucinations. Objectives: Presence hallucinations (PH) being among the most prevalent MH in PD, we used a robotic procedure delivering somatomotor conflicts inducing PH experimentally to investigate whether sensitivity to such robot-induced PH aids in detecting cognitive differences between patients with MH and without hallucinations. Methods: 31 PD patients with MH (PD-MH) and 37 without hallucinations (PD-nH) underwent neuropsychological assessment and the robotic procedure inducing PH. The sensitivity to report robot-induced PH was analyzed in relation to cognitive performance in neuropsychological tests. Results: PD-MH patients reported more robot-induced PH than PD-nH patients, supporting previous findings. While both groups showed comparable performance in neuropsychological testing, we found a significant association between increased sensitivity to the PH-induction and poorer performance in frontal subcortical cognitive functions, in PD-MH patients, but not in PD-nH patients. Conclusions: These findings demonstrate that sensitivity to robot-induced PH reveals a previously undetected link between MH and frontal subcortical cognitive deficits in PD, pointing to shared underlying mechanisms between executive dysfunction and somatomotor processes involved in MH. This approach offers a novel and clinically valuable means of identifying early cognitive vulnerability that assessments relying only on standard testing may overlook.


  • Open Access

    Consenso de expertos españoles sobre el uso de levodopa inhalada para el tratamiento de las fluctuaciones en la enfermedad de Parkinson

    by J. Pagonabarraga, M. Blázquez-Estrada, E. Freire-Álvarez, L. López-Manzanares, N. López-Ariztegui, Á. Sánchez-Ferro, D. Santos-García


  • Open Access

    Spontaneous speech and language measures as predictive biomarkers of clinically meaningful disease progression and neurodegeneration in Huntington’s disease

    by Arnau Puig-Davi, Carla Franch-Marti, Lara Caler-Gameiro, Jesus Perez-Perez, Gonzalo Olmedo-Saura, Jon Rodriguez-Antiguedad, Anna Vázquez-Oliver, Elisa Rivas-Asensio, Laura Perez-Carasol, Margarita Rubio-Romera, et al.

    Huntington’s disease (HD) is characterized by heterogeneous rates of clinical progression, complicating patient monitoring and clinical trial design. Although speech and language alterations are increasingly recognized as part of the HD cognitive phenotype, their value as short-term prognostic biomarkers of clinically meaningful disease progression and neurodegeneration remains unestablished. In this prospective 12-month longitudinal study, we investigated whether objectively quantified spontaneous speech and language measures predict short-term clinically meaningful progression and relate to biomarkers of neurodegeneration in HD. Eighty-six participants (42 manifest HD, 24 premanifest gene carriers, and 20 healthy controls) underwent baseline spontaneous speech assessment, structural MRI, and plasma neurofilament light chain (NfL) quantification. Clinically meaningful worsening was defined using validated minimal clinically important difference thresholds in the composite Unified Huntington’s Disease Rating Scale (cUHDRS). Spontaneous speech and language measures progressively deteriorated across disease stages and were associated with reduced cortico-subcortical gray matter volume in distributed associative and integrative regions. In manifest HD, logistic regression analyses revealed that baseline language integrity independently predicted clinically meaningful worsening at 12 months (OR = 3.840, 95% CI = 1.46–13.33; AUC = 0.783). Combining speech-derived measures with plasma NfL improved discrimination accuracy of individuals with accelerated clinical progression (AUC = 0.807). Spontaneous speech represents an early, accessible and sensitive marker of neurodegeneration in HD. The combination of speech and language derived measures and plasma NfL enables accurate identification of individuals at risk of accelerated, clinically meaningful disease progression, supporting their potential utility as short-term prognostic biomarkers for clinical trials enrichment and stratification.